Thompson Davis & Co’s Anixa Biosciences ANIX Stock Holding History

Thompson Davis & Co’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-250	Closed	-$1K	–	691
2017 Q3	$1K	Buy	+250	New	+$275	﹤0.01%	1054

Other funds holding ANIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DIA

Denver Investment Advisors Denver, Colorado $1.89B AUM 7.9% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

CAM

Concorde Asset Management Ann Arbor, Michigan $204M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Thompson Davis & Co's ANIX Position: Q4 2017 in Review

Thompson Davis & Co sold out of Anixa Biosciences (ANIX) in Q4 2017, closing a stake of 250 shares — an estimated $1K sold.

Thompson Davis & Co first reported a position in ANIX in Q3 2017 and held it in 1 quarter. The position peaked at $1K in Q3 2017. 18 funds tracked by Wall St. Rank hold ANIX as of Q4 2017.

Thompson Davis & Co reported no remaining Anixa Biosciences position as of Q4 2017 after selling out during the quarter.
Thompson Davis & Co sold 250 Anixa Biosciences shares in Q4 2017, an estimated $1K.
Thompson Davis & Co first reported a position in Anixa Biosciences in Q3 2017 and held it in 1 quarter.
Thompson Davis & Co's Anixa Biosciences position peaked at $1K in Q3 2017.
18 funds tracked by Wall St. Rank held Anixa Biosciences as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.